Integrative OUD Care Success With Chiropractic Rehabilitation

Integrative OUD care combined with chiropractic rehabilitation offers unique approaches for sustained recovery and health.

Abstract: A Compassionate, Evidence-Based Approach to Complex OUD Cases

Welcome to Health Voice 360. As a practitioner dedicated to integrating chiropractic and advanced practice nursing principles, I am Dr. Alexander Jimenez, and I am privileged to share insights that bridge disciplines for a holistic, patient-centered approach to health. Today, we are delving into one of the most pressing public health challenges of our time: opioid use disorder (OUD), specifically its management within what we term “special populations.” These groups—individuals with co-occurring mental health conditions, pregnant patients, adolescents, and older adults—face unique physiological, psychological, and social challenges that demand a nuanced and evidence-based treatment strategy. This educational post synthesizes the latest research, clinical guidelines, and my own clinical observations to provide a comprehensive framework for healthcare professionals and clear, empowering information for patients and their families.

The intersection of OUD with other complex medical and life circumstances is not a niche issue; it is the reality for millions. According to the 2022 National Survey on Drug Use and Health from SAMHSA, a staggering 21.5 million adults in the U.S. live with a co-occurring mental health and substance use disorder. Alarming statistics show that nearly 40% of these individuals receive no treatment whatsoever. This treatment gap represents a critical failure in our healthcare system and a call to action for every provider. In this post, we will dissect the intricate relationship between OUD and conditions like Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), and Post-Traumatic Stress Disorder (PTSD). We will explore validated screening tools such as the PHQ-9, GAD-7, and PCL-5, and discuss why a trauma-informed care model is not just beneficial but essential for fostering trust and promoting healing. We will also navigate the pharmacological landscape, examining the first-line use of SSRIs and SNRIs and their critical interactions with OUD medications like buprenorphine, methadone, and naltrexone, paying close attention to risks like serotonin syndrome and QTc prolongation.

Furthermore, we will address the profoundly sensitive and high-stakes arena of OUD in pregnancy. We will review the data showing a dramatic rise in OUD at delivery and the subsequent increase in Neonatal Opioid Withdrawal Syndrome (NOWS). A key focus will be on destigmatizing this patient population and promoting universal screening with tools like the 4 P’s and CRAFFT. We will clarify why medications for opioid use disorder (MOUD), specifically buprenorphine and methadone, are the recommended standard of care, leading to improved maternal and neonatal outcomes, and why medically supervised withdrawal is strongly discouraged due to the high risk of relapse and overdose. The post will also provide an in-depth look at OUD in adolescents. In this group, overdose deaths have surged despite decreased overall use, driven by the proliferation of illicitly manufactured fentanyl. We’ll discuss age-appropriate screening, the importance of confidentiality, and the approved use of MOUD in this vulnerable population. Finally, we’ll turn our attention to older adults, another growing demographic affected by OUD, examining the dose adjustments and careful monitoring required because of age-related changes in hepatic and renal function. We will also tackle the common clinical dilemma of managing patients on both MOUD and other Central Nervous System (CNS) depressants, such as benzodiazepines, clarifying the FDA’s risk-benefit guidance that prioritizes treating OUD to save lives.

My goal with this comprehensive discussion is to empower you with the knowledge to approach these complex cases with confidence, compassion, and a commitment to evidence-based practice. By understanding the underlying physiology, the rationale behind treatment protocols, and the human element at the heart of every case, we can collectively improve outcomes and offer hope to those who need it most.

Understanding the Overlap: Opioid Use Disorder and Co-Occurring Mental Health Conditions

As a clinician, I frequently observe that substance use disorders rarely exist in a vacuum. More often than not, they are intertwined with underlying mental health struggles. The data from the Substance Abuse and Mental Health Services Administration (SAMHSA) is sobering. The 2022 National Survey on Drug Use and Health revealed that approximately 21.5 million adults in the United States are navigating a co-occurring disorder, meaning they live with both a mental health condition and a substance use disorder.

The treatment landscape for these individuals is deeply concerning. Of this large population, about 60% received some form of treatment—either for their substance use or their mental health, but rarely for both in an integrated manner. Shockingly, a full 40% received no treatment at all. Among those who did seek help, the majority were treated for their mental health condition, while the substance use disorder often went unaddressed. This siloed approach is a fundamental flaw in our healthcare system. Treating one condition without acknowledging the other is like trying to fix a roof leak while ignoring a crack in the foundation; the structure will ultimately remain unstable.

When we focus specifically on individuals with opioid use disorder (OUD), the prevalence of co-occurring mental health conditions is particularly high. The literature consistently highlights three primary diagnoses:

• Major Depressive Disorder (MDD): This condition can affect up to 50% of individuals with a substance use disorder. From my clinical experience, patients often describe using opioids not just for physical pain but to numb emotional pain, creating a vicious cycle where the substance temporarily alleviates depressive symptoms but ultimately exacerbates the condition over time.
• Anxiety Disorders: Approximately 30% of individuals with OUD also struggle with significant anxiety. The calming, euphoric effect of opioids can become a form of self-medication for overwhelming worry and panic, but the subsequent withdrawal period often triggers rebound anxiety, intensifying the perceived need for the substance.
• Post-Traumatic Stress Disorder (PTSD): Nearly 20% of individuals with OUD have a co-occurring PTSD diagnosis. Research indicates that this comorbidity is more common in females and tragically increases the risk of both overdose and suicide attempts. Trauma can lead to a state of chronic hypervigilance and emotional dysregulation, and opioids can feel like a powerful escape from intrusive memories and distressing physiological sensations.

The Critical Role of Screening in Integrated Care

Given this high rate of co-occurrence, proactive and universal screening is not just good practice—it’s an ethical imperative. We cannot wait for patients to volunteer this information; many may not even connect their substance use with their emotional state or may feel too stigmatized to discuss it. We must build screening into our routine workflows.

Commonly Used Screening Tools

In primary care and specialized settings, several validated, easy-to-administer tools can help us identify these co-occurring conditions.

• PHQ-9 (Patient Health Questionnaire-9): This is the gold standard for screening, diagnosing, and monitoring depression severity. It consists of nine questions that align directly with the DSM-5 criteria for major depressive disorder. Patients rate how often they have been bothered by symptoms like anhedonia, sleep disturbance, and feelings of worthlessness over the past two weeks. The score helps us classify the depression as mild, moderate, or severe, which is crucial for guiding our treatment decisions.
• GAD-7 (Generalized Anxiety Disorder-7): Similar to the PHQ-9, this seven-item tool assesses the severity of anxiety. It asks about symptoms like uncontrollable worrying, restlessness, and irritability. The score provides a clear metric for both initial diagnosis and for tracking treatment response over time.
• PCL-5 (Post-Traumatic Stress Disorder Checklist 5): While screening for depression and anxiety is becoming more common, PTSD is often overlooked. This is a significant gap, especially in the OUD population. The PCL-5 is a 20-question self-report measure that aligns with the DSM-5 criteria for PTSD. It asks patients to rate how much they have been bothered by specific symptoms over the past month, including nightmares, flashbacks, avoidance behaviors, anhedonia, and hypervigilance. A score between 31 and 33 is generally considered the clinical cut-off, suggesting that a formal diagnostic assessment and treatment are warranted. Just as importantly, this tool can be used to monitor progress; a reduction of 10 points or more is considered a clinically significant response to treatment.

Implementing Trauma-Informed Care: A Foundational Principle

For any patient, but particularly for those with OUD and a history of trauma, a trauma-informed care approach is non-negotiable. This is not a specific technique but a philosophical shift in how we view and interact with our patients. It moves away from the question, “What is wrong with you?” to the more compassionate and constructive question, “What has happened to you?” This framework is built on six core principles:

1. Safety: We must create an environment—both physical and emotional—where patients feel secure. This means ensuring privacy, being mindful of triggers, and maintaining a calm, predictable setting. In my practice, this translates to clear communication about what to expect during a visit and ensuring the patient feels in control of their physical space.
2. Trustworthiness and Transparency: Building trust is paramount, especially with individuals whose systems or people have let them down in the past. This involves being honest, open, and reliable. We must be clear about treatment plans, potential side effects, and clinic policies. There should be no surprises or hidden contingencies that can feel like a betrayal.
3. Peer Support: Integrating individuals with lived experience into the care team can be incredibly powerful. Peer support specialists can help establish trust, model recovery, and provide a level of empathy that a clinician alone cannot. They serve as living proof that recovery is possible, which can be a profound source of empowerment for patients.
4. Collaboration and Mutuality: This principle moves us away from a paternalistic, “doctor-knows-best” model toward a partnership. We work with our patients, not on them. We make decisions together, respecting the patient’s expertise in their own life. This collaborative spirit ensures that care is truly patient-centered and tailored to their unique needs and goals.
5. Empowerment, Voice, and Choice: True healing happens when individuals regain a sense of agency over their lives. We facilitate this by offering choices wherever possible—whether it’s in scheduling, treatment modalities, or goal-setting. We must consistently reinforce that they drive their own care journey.
6. Cultural, Historical, and Gender Issues: We must recognize that each patient’s experience is shaped by their unique cultural background, historical context, and gender identity. Our own lived experiences are not universal. We must be humble, curious, and willing to learn about the sociocultural factors and systemic biases that may be influencing our patients’ health, perceptions, and interactions with the healthcare system.

Evidence-Based Therapeutic and Pharmacological Interventions

Once a co-occurring condition is identified, an integrated treatment plan is essential. This typically involves a combination of therapy and medication.

Therapeutic Modalities

While many forms of therapy can be beneficial, certain evidence-based approaches have demonstrated particular efficacy for these co-occurring conditions.

• Cognitive Behavioral Therapy (CBT): This is a cornerstone of treatment for both depression and anxiety. CBT helps patients identify, challenge, and reframe negative thought patterns (cognitions) and maladaptive behaviors. For a patient with OUD and depression, CBT might focus on challenging thoughts of hopelessness that trigger cravings and developing healthy coping strategies to replace substance use.
• Therapies for PTSD: For PTSD, more specialized, trauma-focused therapies are recommended. It’s crucial to refer patients to therapists trained in these specific modalities:

• • Prolonged Exposure (PE): This therapy involves gradually and systematically confronting trauma-related memories, feelings, and situations in a safe environment, helping to reduce the power of the trauma to trigger fear and avoidance.
  • Cognitive Processing Therapy (CPT): CPT focuses on how the trauma has impacted one’s beliefs about oneself, others, and the world. It helps patients challenge and modify unhelpful beliefs related to the trauma, such as self-blame or the belief that the world is entirely dangerous.
  • Eye Movement Desensitization and Reprocessing (EMDR): EMDR uses bilateral stimulation (such as eye movements or tapping) while a patient focuses on traumatic memories. The exact mechanism is still being studied, but it appears to help the brain reprocess these memories, reducing their emotional intensity and vividness.

As prescribing clinicians, we are responsible for building a network of trusted therapists proficient in these evidence-based practices so we can make effective referrals.

First-Line Medications for MDD, GAD, and PTSD

Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) are the first-line pharmacological treatments for depression, anxiety, and PTSD. While many medications in these classes are used, it helps to know their specific FDA-approved indications and distinct side effect profiles.

• Paroxetine (Paxil): An SSRI indicated for all three conditions (MDD, GAD, PTSD). A key consideration is its relatively high rate of sexual dysfunction, a common side effect across this class but more pronounced with paroxetine. It also has a shorter half-life, which can lead to discontinuation syndrome if doses are missed.
• Sertraline (Zoloft): An SSRI indicated for MDD and PTSD. It is known for a higher incidence of gastrointestinal (GI) side effects, such as nausea and diarrhea, particularly when initiating treatment. These symptoms are often transient and resolve within a few weeks.
• Fluoxetine (Prozac): An SSRI indicated for MDD. Its most notable feature is its long half-life. This can be an advantage for patients who may struggle with medication adherence, as a missed dose is less likely to cause withdrawal symptoms. However, this same property makes it more dangerous in an overdose attempt, as the drug remains in the system for an extended period.
• Escitalopram (Lexapro): An SSRI indicated for MDD and GAD. It is generally one of the best-tolerated SSRIs, with a clean side effect profile, though it is associated with some weight gain.
• Duloxetine (Cymbalta): An SNRI indicated for MDD and GAD. It has the advantage of having less sexual dysfunction than many SSRIs. It also has analgesic properties, which can be beneficial for patients with co-occurring chronic pain, a common scenario in the OUD population.
• Venlafaxine (Effexor): An SNRI indicated for MDD and GAD. It is associated with GI side effects and potential weight gain. A crucial point with venlafaxine is the risk of hypertension, especially at higher doses, due to its norepinephrine activity. Blood pressure should be monitored regularly. It also has a short half-life and can cause significant discontinuation syndrome.

Navigating Drug Interactions: MOUD and Psychiatric Medications

Prescribing SSRIs or SNRIs to a patient on medication for opioid use disorder (MOUD) requires careful consideration of potential drug-drug interactions. The benefits of treating the underlying mental health condition are profound—research consistently shows it increases retention in OUD treatment—but we must be vigilant about the risks.

Buprenorphine and Serotonergic Agents

Buprenorphine, a partial opioid agonist, does possess some serotonergic properties. When combined with an SSRI or SNRI, there is a theoretical, albeit low, risk of serotonin syndrome. However, in my clinical judgment and supported by the literature, the benefit of effectively treating a patient’s depression or anxiety far outweighs this small risk. Untreated depression is a major driver of relapse and a significant risk factor for overdose. The key is patient education—we must have an open conversation about the risks and benefits and instruct patients on the signs of serotonin syndrome.

Serotonin Syndrome: A Clinical Reminder

Serotonin syndrome is a potentially life-threatening condition caused by excessive serotonergic activity in the central nervous system. The mnemonic SHIVERS can be a helpful way to remember the key signs and symptoms:

• Shivering
• Hyperreflexia and Myoclonus (involuntary muscle twitching)
• Increased Temperature (fever)
• Vital Sign Abnormalities (tachycardia, hypertension)
• Encephalopathy (mental status changes, confusion, agitation)
• Restlessness
• Sweating (diaphoresis)

If a patient presents with this constellation of symptoms, especially the combination of neuromuscular excitement (hyperreflexia, myoclonus) and autonomic instability, immediate medical evaluation is required.

Methadone and QTc Prolongation

Methadone, a full opioid agonist, is well-known for its potential to prolong the QTc interval on an electrocardiogram (ECG). A prolonged QTc interval increases the risk of a dangerous ventricular arrhythmia called Torsades de Pointes, which can lead to syncope and sudden cardiac death. This risk is compounded when methadone is combined with other medications that also prolong the QTc.

Many psychiatric medications, including some SSRIs and antipsychotics, carry this risk. Citalopram (Celexa) is particularly noteworthy; doses above 40 mg per day (or 20 mg in patients over 60) are not recommended due to the risk of QTc prolongation. Venlafaxine also has a slightly higher risk compared to other SSRIs/SNRIs.

When managing a patient on methadone who requires one of these medications, a structured monitoring protocol is essential:

1. Obtain a baseline ECG before initiating the second QTc-prolonging agent.
2. Monitor for symptoms: Regularly ask the patient about palpitations, dizziness, lightheadedness, syncope (fainting), chest pain, or shortness of breath.
3. Repeat the ECG: Obtain a follow-up ECG after the new medication has reached a steady state (typically after five half-lives).
4. Establish thresholds: According to many guidelines, a QTc interval exceeding 450 milliseconds for men or 460 milliseconds for women warrants close monitoring or a change in therapy. A QTc over 500 ms often necessitates discontinuation of the offending agent(s).
5. Perform annual ECGs as part of routine monitoring for all patients on stable methadone therapy.

Naltrexone and Mental Health Warnings

Naltrexone, an opioid antagonist, carries its own unique considerations. The medication itself has a warning for potentially causing or worsening depression or suicidality. This is particularly relevant when we consider that SSRIs and SNRIs also carry a black box warning for increased risk of suicidal thinking and behavior, especially in children, adolescents, and young adults (up to age 24).

This does not mean these medications are contraindicated. In fact, for many patients, the risk of not treating their depression is far greater. Individuals with untreated depression often use substances like opioids or alcohol to cope, which is one of the highest risk factors for death by suicide. The key is, once again, a transparent risk-benefit discussion with the patient, close monitoring for any worsening of mood or emergence of suicidal ideation, and ensuring they have a robust safety plan.

Case Study in Integrated Care

Let’s apply these concepts to a clinical scenario.

• Patient: A 32-year-old divorced female, mother of two, working part-time in retail.
• History: Chronic low back pain from degenerative disc disease, which led to opioid misuse. She is currently stable on buprenorphine/naloxone 8 mg three times a day for severe OUD. Her father has a history of alcohol use disorder, and her mother has depression. She lives with her mother and children, has a limited support network, but attends peer recovery groups. She has a history of intimate partner violence.
• Presentation: She presents for a follow-up. While she denies any return to non-prescribed opioid use, she reports debilitating symptoms of depression and anxiety. She feels exhausted, overwhelmed by worry, and is unable to enjoy time with her children. She states, “I am staying away from pills, but I feel like I am drowning most days.” She denies active suicidal ideation.

Clinical Approach:

1. Screening: We administer the standard screening tools.

• • PHQ-9: Score of 18 (Moderately Severe Depression)
  • GAD-7: Score of 15 (Severe Anxiety)
  • PCL-5: Score of 10 (Does not indicate PTSD, though her history of IPV warrants continued vigilance).

• Assessment: A urine drug screen is positive for buprenorphine and negative for other substances, confirming her adherence and report.
• Treatment Plan:

• • MOUD: Continue buprenorphine/naloxone. She is stable on this medication, and it is the cornerstone of her recovery from OUD.
  • Pharmacotherapy for MDD/GAD: Initiate a first-line agent, such as sertraline or escitalopram. We would start at a low dose and titrate up, monitoring for efficacy and side effects. We must discuss the low risk of serotonin syndrome and educate her on the symptoms.
  • Therapy: Refer her for Cognitive Behavioral Therapy (CBT) to address the thought patterns and behaviors contributing to her depression and anxiety.
  • Harm Reduction: Prescribe naloxone and ensure she and her mother know how to use it. This is standard practice for all patients with OUD.
  • Safety Planning: Discuss the 988 Suicide & Crisis Lifeline and other emergency resources, empowering her with a plan in case of a crisis, even though she currently denies suicidal ideation.

This integrated plan addresses her OUD, her co-occurring mental health conditions, and her safety, providing a comprehensive and compassionate path forward.

Opioid Use Disorder in Pregnancy: A High-Stakes Challenge

The intersection of opioid use disorder and pregnancy is a particularly vulnerable and often stigmatized area of healthcare. The statistics are alarming and paint a picture of a rapidly escalating crisis.

• From 1999 to 2014, the incidence of OUD in pregnant individuals increased fourfold.
• From 2010 to 2017 alone, OUD documented at the time of delivery increased by 131%.

This maternal crisis has a direct and immediate impact on newborns. The incidence of Neonatal Opioid Withdrawal Syndrome (NOWS) has skyrocketed in parallel.

• From 2002 to 2009, NOWS cases increased fivefold.
• From 2010 to 2017, cases increased by another 82%.
• Current data from 2021 indicates that a baby is born experiencing symptoms of opioid withdrawal every 24 minutes in the United States.

These rates are often higher in rural areas, where access to specialized care may be limited.

Overcoming Stigma: The Greatest Barrier to Care

For pregnant individuals with OUD, stigma is perhaps the most significant barrier to seeking and receiving care. They are often subjected to deeply harmful stereotypes—labeled as “unfit mothers,” “drug seekers,” or “criminals.” Tragically, this poor treatment often comes from healthcare staff themselves, through both overt verbal judgments and subtle non-verbal cues of disapproval.

These negative experiences are not only counterproductive to recovery; they can be dangerous. When a patient feels judged and shamed, they are less likely to be forthcoming about their substance use, less likely to attend prenatal appointments, and more likely to disengage from care altogether. This can trigger a return to use and significantly increase the risk of overdose. Our primary role as clinicians is to create a safe, non-judgmental space where these patients feel seen, heard, and supported.

Universal Screening in Pregnancy

Because of the high prevalence and the dangers of missed diagnoses, universal screening for substance use should be a standard component of all prenatal care. We must not selectively screen patients based on our own biases about who we think might be using substances. Several simple, validated tools can be integrated into the initial prenatal visit.

• The 4 P’s: A quick, easy-to-remember mnemonic. A “yes” to any question should trigger a more in-depth assessment.

• • Parents: Did your parents have a problem with alcohol or other drug use?
  • Partner: Does your partner have a problem with alcohol or drug use?
  • Past: In the past, have you had difficulties in your life because of alcohol or other drug use?
  • Present: In the past month, have you drunk any alcohol or used other drugs?

• NIDA Quick Screen: This tool asks about substance use within the past year. For women, it specifically flags drinking four or more standard drinks on any given day, any tobacco use, or any use of other drugs. A positive screen prompts a more detailed substance-specific inquiry.
• CRAFFT: This tool is validated for individuals up to age 26 and is excellent for screening adolescents and young adults. It screens for problematic behaviors associated with substance use. Two or more positive answers indicate a need for further assessment.

• • Car: Have you ever ridden in a car driven by someone (including yourself) who was high or had been using?
  • Relax: Do you ever use alcohol or drugs to relax or feel better about yourself?
  • Alone: Do you ever use alcohol or drugs while you are alone?
  • Forget: Do you ever forget things you did while using?
  • Family/Friends: Do your family or friends ever tell you to cut down?
  • Trouble: Have you ever gotten into trouble while you were using?

Understanding the Risks of Untreated OUD in Pregnancy

Untreated OUD poses significant risks to both the pregnant individual and the fetus. These complications often arise from the chaotic cycle of intoxication and withdrawal, which causes physiological instability, as well as the inconsistent prenatal care that often accompanies active substance use. The primary risks include:

• Placental abruption (the placenta detaching from the uterine wall)
• Fetal growth restriction
• Preterm birth
• Stillbirth
• Maternal overdose, which is a leading cause of maternal mortality in some states.

Neonatal Opioid Withdrawal Syndrome (NOWS)

It is crucial to use precise language when discussing the effects of in-utero opioid exposure on a newborn. The term previously used was Neonatal Abstinence Syndrome (NAS). The updated and more accurate term is Neonatal Opioid Withdrawal Syndrome (NOWS).

A critical point of education for both staff and families is that babies cannot be “addicted.” Addiction, as defined by the DSM-5, is a complex behavioral disorder characterized by a pattern of compulsive use despite negative consequences. A newborn cannot exhibit these behaviors. What they can experience is physical dependence and subsequent withdrawal when the exposure to the substance they received in utero is abruptly stopped at birth.

Symptoms of NOWS typically appear within 24 to 72 hours after birth and can include:

• Shaking and tremors (hypertonicity)
• Poor feeding or an uncoordinated suck
• Excessive, high-pitched crying and irritability
• Fever and sweating
• Diarrhea and vomiting
• Sleep problems

Two primary methods are used to assess the severity of NOWS:

• Eat, Sleep, Console (ESC): A simplified, function-based approach that is gaining popularity. It assesses the baby’s ability to perform three basic functions:

• • Eat: Can the baby eat at least one ounce per feeding?
  • Sleep: Can the baby sleep for at least one hour uninterrupted?
  • Console: Can a caregiver console the baby within 10 minutes?

If the baby can do these three things, pharmacological intervention is often not needed.

• Finnegan Neonatal Abstinence Scoring System: This is a much more detailed, 21-item assessment that scores the severity of various CNS, metabolic, and gastrointestinal symptoms, such as the duration of high-pitched crying, the intensity of the Moro reflex, seizures, sweating, respiratory rate, and yawning. While comprehensive, it is more complex and time-consuming to administer than the ESC method.

NOWS can last from several days to several weeks, depending on the specific opioid the mother was using and its half-life. The most reassuring message we can give to mothers is that, with proper care, there are no known long-term physical or intellectual problems associated with being born with NOWS.

The initial treatment for NOWS is non-pharmacological. The baby should room-in with the mother, which promotes bonding and reduces stress for both. Other key interventions include swaddling, encouraging skin-to-skin contact, and breastfeeding. If these measures are insufficient and the withdrawal symptoms are severe, pharmacological intervention may be necessary. Morphine is typically the first-line medication used to manage symptoms, followed by a slow taper. Secondary medications like clonidine or phenobarbital may be used in more complex cases. It is critical to note that naloxone should never be administered to a newborn, as it can precipitate severe, life-threatening withdrawal.

Breastfeeding and OUD: The Benefits are Clear

Unless there are specific contraindications, breastfeeding should be strongly encouraged for mothers with OUD. The benefits for both mother and child are immense and are the same as for any other dyad.

• Neonatal Benefits: Decreased risk of asthma, leukemia, obesity, ear infections, SIDS, and diabetes.
• Maternal Benefits: Decreased risk of breast and ovarian cancer, postpartum depression, and diabetes. It also promotes faster recovery from childbirth, decreased maternal stress, and crucially, increased mother-child bonding, which can reduce the risk of maternal neglect.

There are a few clear contraindications to breastfeeding:

• Return to use of non-prescribed or illicit substances.
• A diagnosis of HIV.
• Concurrent use of other medications that are contraindicated in breastfeeding.

It is essential to state clearly that buprenorphine and methadone are safe with breastfeeding. The amount of medication transferred through breast milk is minimal and is far outweighed by the extensive benefits of breastfeeding for both mother and infant.

MOUD: The Standard of Care in Pregnancy

The evidence is unequivocal: for pregnant individuals with OUD, medications for opioid use disorder (MOUD) are the first-line treatment and the standard of care. Leading organizations universally support this recommendation, including the American College of Obstetricians and Gynecologists (ACOG), SAMHSA, and the World Health Organization (WHO).

The two primary medications used are:

• Buprenorphine: A partial opioid agonist.
• Methadone: A full opioid agonist.

Both medications work by stabilizing opioid levels in the body, which prevents the dangerous cycle of intoxication and withdrawal. This physiological stability leads directly to improved maternal and neonatal outcomes. Mothers on MOUD are more likely to engage in prenatal care, and their babies are more likely to have a normal birth weight and be born at full term. While babies exposed to buprenorphine or methadone may still experience NOWS, the syndrome is often less severe. It requires a shorter duration of treatment compared to babies exposed to heroin or short-acting prescription opioids. MOUD has no evidence of causing congenital disabilities.

Medically assisted withdrawal or “detox” is strongly NOT recommended during pregnancy. This approach carries a very high rate of return to use. A relapse after a period of abstinence is extremely dangerous because the individual’s tolerance has decreased, placing them at an exceptionally high risk of a fatal overdose.

Naltrexone, the opioid antagonist, is not a first-line treatment in pregnancy but is not strictly contraindicated. It could be considered for a highly motivated patient who has already completed withdrawal before becoming pregnant, but this requires a detailed discussion about the risks, including the risk of relapse and overdose if the medication is discontinued.

Psychosocial therapy and support should always be recommended as an adjunct to MOUD to address the behavioral and psychological aspects of the disorder.

Case Study in Pregnancy and OUD

Let’s consider another clinical case.

• Patient: A 28-year-old female, G2P1 (second pregnancy, one prior birth), at 18 weeks gestation.
• History: Mild asthma, generalized anxiety disorder. Lives with a supportive partner, works part-time, and denies alcohol or tobacco use.
• Presentation: She reports daily misuse of prescription oxycodone, taking approximately 60 mg per day. She is aware of the risks to her pregnancy but is unable to stop due to fear of withdrawal and intense cravings. She is highly motivated for treatment, stating, “I want to be healthy for my baby and myself. I’ve tried quitting on my own but I can’t.”

Clinical Approach:

1. Assessment:

• • Urine Drug Screen: Positive for oxycodone, negative for other substances.
  • Labs: A standard prenatal panel is drawn (CBC, CMP, HIV, hepatitis panel, STI panel), all of which are within normal limits.

• Treatment Plan:

• • MOUD Initiation: Start buprenorphine. Because she is on a short-acting opioid (oxycodone), she can be initiated 12-24 hours after her last dose, once she is in mild to moderate withdrawal.
  • Titration: Begin with an initial dose of 2-4 mg of buprenorphine and titrate upwards as tolerated, aiming for a maintenance dose (up to a maximum of 24 mg/day) that eliminates cravings and withdrawal symptoms.
  • Harm Reduction: Prescribe naloxone for her and her partner.
  • Coordination of Care: Refer her immediately for prenatal care with an OB/GYN, ideally one experienced in managing pregnant patients with OUD.
  • Support: Recommend psychosocial support, such as counseling or a support group for pregnant and parenting individuals in recovery.
  • Postpartum Planning: Encourage breastfeeding postpartum, assuming no contraindications arise, and discuss the plan for her continued OUD treatment and the baby’s monitoring for NOWS after delivery.

This plan offers her the best chance for a healthy pregnancy and a healthy baby, addressing her OUD with an evidence-based, compassionate approach.

The Emerging Crisis: Opioid Use in Adolescents

While overall substance use among adolescents has seen some decline, the landscape of opioid use has become tragically more lethal. The statistics on overdose deaths in this population are a stark warning.

• From 2019 to 2020, overdose deaths among 14- to 18-year-olds increased by 94%.
• From 2020 to 2021, overdose deaths rose another 20%.

The paradox is that while fewer teens may be experimenting with opioids, the drugs they encounter are exponentially more dangerous. The primary driver of this surge in deaths is the proliferation of illicitly manufactured fentanyl (IMF) and its analogs, which are often pressed into counterfeit pills made to look like legitimate prescription medications (like oxycodone or alprazolam) or mixed into other illicit drugs. Deaths involving IMFs in this age group increased by 183% in this short period.

An analysis of these tragic deaths reveals several key factors:

• 40% of the adolescents had a known history of mental health conditions.
• 35% had a prior history of opioid use.
• Only 5% had ever received treatment for opioid use disorder.

This massive treatment gap highlights a systemic failure to identify and engage at-risk youth.

Identifying Protective and Risk Factors in Adolescents

To effectively intervene, we must understand the factors that can either protect an adolescent from or predispose them to substance use.

Protective Factors:

• Strong family engagement and open communication.
• Guardian disapproval of substance use.
• School connectedness and a sense of belonging.
• High self-efficacy and a belief in one’s ability to cope with stress.

Risk Factors:

• Adverse social determinants of health (poverty, unstable housing, community violence).
• Use of other substances (alcohol, cannabis, tobacco).
• Early age of initiation of any substance use.
• A personal history of impulsivity or risk-taking behavior.
• Co-occurring psychiatric disorders (ADHD, depression, anxiety).
• A history of maltreatment (abuse or neglect).
• A family history of substance use disorders.

Screening for these risk factors can help us identify which young patients may need more targeted prevention efforts and closer monitoring.

Screening Adolescents: The Importance of Confidentiality

When screening adolescents for substance use, establishing confidentiality is the first and most critical step. Before asking any sensitive questions, we must be completely transparent about the limits of confidentiality under state laws and institutional policies. We need to clearly explain what we can keep between us and the circumstances that would require us to disclose information to a parent or guardian (e.g., imminent risk of harm to self or others). Breaking a youth’s trust by disclosing information they believed was confidential can irreparably damage the therapeutic relationship.

Whenever possible, it is recommended to have one-on-one time with the adolescent patient, without a parent in the room. This private time is essential for building rapport and creating a safe space for honest conversation, education, and harm reduction counseling.

Several screening tools are validated for this population:

• S2BI (Screening to Brief Intervention): This tool asks about the frequency of use (never, once/twice, monthly, weekly) for various substances over the past year.
• BSTAD (Brief Screener for Tobacco, Alcohol, and other Drugs): This tool asks for the specific number of days a substance was used in the past year and includes a comprehensive list of illicit drugs and misused prescription medications.
• CRAFFT: As discussed earlier, this tool is excellent for screening adolescents as it focuses on the negative consequences and behaviors associated with substance use.

Treatment Recommendations for Adolescents with OUD

The treatment approach for adolescents must be comprehensive, developmentally appropriate, and involve the family whenever possible.

1. Naloxone, Naloxone, Naloxone: This cannot be overstated. The adolescent, their family, and their close friends should all have access to naloxone and be trained on how to use it. Many schools are now stocking naloxone, but personal access is key. We should discuss high-risk scenarios (e.g., using alone, using a new supply) and help them develop a safety plan.
2. Behavioral Health Services: Therapy is a cornerstone of treatment. This can occur in various settings, including outpatient clinics, intensive outpatient programs, and even school-based health centers. Family therapy is often a crucial component to improve communication and address family dynamics that may contribute to substance use.
3. Medications for Opioid Use Disorder (MOUD):

• • Buprenorphine is FDA-approved for adolescents aged 16 and older. For a teen with moderate to severe OUD, buprenorphine is the recommended first-line treatment. It is highly effective at reducing illicit opioid use and improving retention in care.
  • Naltrexone and methadone are currently only FDA-approved for individuals aged 18 and older.
  • The American Society of Addiction Medicine (ASAM) is developing updated guidelines for treating adolescents and transition-age youth, anticipated in 2026. These will likely provide more nuanced guidance on using MOUD in this population.

Case Study in Adolescent OUD

Let’s examine a case that is unfortunately all too common.

• Patient: A 16-year-old female in 11th grade. Formerly a competitive soccer player, she now has declining grades and poor school attendance.
• History: She sustained an ankle fracture at age 15, which required surgery and a postoperative prescription for oxycodone. Her father has alcohol use disorder (in remission), and her mother has depression. She lives with her mother and younger brother. After her injury, she drifted from her previous peer group and began associating with older friends who misuse opioids.
• Presentation: She is brought to the emergency department by her mother after being found extremely drowsy and nauseated. She admits to snorting heroin daily for the past six months. She explains that after her surgery, she continued taking leftover oxycodone pills because they made her feel calm. When her prescription ran out, her new peers introduced her to heroin as a cheaper, more available alternative. She says, “At first I needed the pills for pain, but then I needed them to feel okay. When I couldn’t get them anymore, heroin was the only thing around.”

Clinical Approach:

1. Assessment:

• • Urine Drug Screen: Positive for heroin. It is also crucial to test for fentanyl. In this case, the screen is negative for fentanyl and other substances. This is a critical harm reduction moment—we must educate her that the next batch of heroin she encounters could be laced with fentanyl, and she would have no way of knowing.

• Treatment Plan:

• • MOUD Initiation: Because she is 16 years old, she is eligible for buprenorphine. We would initiate treatment 12-24 hours after her last heroin use, once withdrawal symptoms emerge.
  • Titration: We would start with a low dose (2 mg) and titrate up as tolerated to a dose that controls her cravings and withdrawal symptoms (up to 24 mg/day).
  • Harm Reduction: We would prescribe naloxone and ensure both she and her mother are trained to use it.
  • Psychosocial Support: A comprehensive plan is essential. This would involve referral to an adolescent substance use treatment program that offers individual therapy, group therapy, and family counseling. Coordinating with her school to develop an academic support plan is also vital.

Enhancing Health Together: Embracing Multidisciplinary Evaluation and Treatment- Video

Other Considerations for Special Populations with OUD

Beyond the groups we’ve discussed in detail, other populations require special consideration in managing OUD.

Opioid Use Disorder in Older Adults

OUD is not just a problem for the young. We are seeing a concerning trend in older adults as well. Since 2013, there has been a threefold increase in OUD diagnoses among adults aged 65-69. This trend is more pronounced among individuals covered by both Medicare and Medicaid than those with Medicare alone. Data also show increased vulnerability among Black Americans, Native Americans, and Alaska Natives in this age group.

When considering MOUD for older adults, caution is key. The principle remains the same: the benefit of treatment to prevent overdose from potent illicit opioids usually outweighs the risk of the medication. However, there are several unique physiological considerations:

• Lack of Data: Older adults (>65) have been systematically underrepresented in the pivotal clinical trials for MOUD, so our guidance is less robust for this population.
• Hepatic and Renal Function: Age-related declines in kidney and liver function can significantly alter drug metabolism and clearance.

• Methadone: If creatinine clearance is less than 10 mL/min (severe renal impairment), a dose reduction of 50-75% should be considered. The liver primarily metabolizes methadone, but significant dose adjustments for hepatic impairment are less clearly defined. We must also remain vigilant about QTc prolongation, which can be a greater risk in older adults who are more likely to be on other QTc-prolonging medications.
• Buprenorphine: No dose adjustment is needed for renal impairment. However, for patients with severe hepatic impairment, a dose reduction should be considered. The long-acting subcutaneous buprenorphine injections are not recommended for patients with moderate to severe liver impairment.

• Increased Risk of Respiratory Depression: With methadone in particular, older adults may be more susceptible to respiratory depression due to altered pharmacokinetics and slower clearance.
• Close Monitoring: Overall, older adults starting on MOUD may require more frequent follow-up visits and closer monitoring of side effects and organ function.

Co-Prescribing MOUD and Other CNS Depressants

One of the most common clinical dilemmas is managing a patient who requires MOUD but is also taking another Central Nervous System (CNS) depressant, most commonly a benzodiazepine. For years, many clinics had strict policies against initiating MOUD for patients on benzodiazepines, fearing the combined risk of respiratory depression.

However, the FDA released a crucial safety communication clarifying its stance on this issue. The agency urged caution about withholding MOUD from patients taking benzodiazepines or other CNS depressants. The rationale is grounded in a risk-benefit analysis:

• The risk of a fatal overdose from combining a prescribed dose of buprenorphine or methadone with a prescribed dose of a benzodiazepine is significantly lower than the risk of a fatal overdose from combining that same benzodiazepine with illicit fentanyl or heroin.

Therefore, the presence of a benzodiazepine is not an absolute contraindication for MOUD. We should not use arbitrary dose limits (e.g., refusing to exceed a certain buprenorphine dose) to “compensate,” as under-treating the OUD can lead to relapse, which is the most dangerous outcome.

The best practice is:

1. Prioritize treating the OUD with an adequate, effective dose of MOUD.
2. Educate the patient thoroughly about the increased risk of sedation and respiratory depression from the combination.
3. Prescribe naloxone and ensure they and their household members know how to use it.
4. If at all possible, develop a plan to taper and discontinue the benzodiazepine slowly. Since benzodiazepines are not a first-line treatment for anxiety disorders, this often involves transitioning the patient to an SSRI or SNRI and providing behavioral therapy.

This guidance also applies to other CNS depressants identified by the FDA, including:

• Sleep medications (e.g., zolpidem, eszopiclone)
• Muscle relaxants (e.g., baclofen, cyclobenzaprine)
• Antipsychotics (e.g., aripiprazole, quetiapine, paliperidone)

While some of these medications are essential for managing severe psychiatric conditions and cannot be discontinued, the principle remains the same: manage the combined risk through education and harm reduction while ensuring the OUD is effectively treated.

Summary

This comprehensive review has navigated the complex and nuanced landscape of treating opioid use disorder in several key special populations. We began by establishing the profound link between OUD and co-occurring mental health conditions like depression, anxiety, and PTSD, underscoring that nearly half of adults with these co-occurring disorders receive no treatment at all. We emphasized the need for universal screening using tools like the PHQ-9, GAD-7, and PCL-5, and the importance of adopting a trauma-informed care model built on safety, trust, and collaboration. We then explored evidence-based treatments, including first-line SSRI/SNRI medications. We carefully examined their critical interactions with MOUD, focusing on the management of risks such as serotonin syndrome with buprenorphine and QTc prolongation with methadone.

Our discussion then moved to the high-stakes arena of OUD in pregnancy. We highlighted the alarming increase in OUD at delivery and subsequent Neonatal Opioid Withdrawal Syndrome (NOWS). The core message was the unequivocal recommendation from ACOG and other leading bodies for MOUD (buprenorphine or methadone) as the standard of care to improve maternal and neonatal outcomes, while strongly advising against medically supervised withdrawal due to the high risk of relapse and overdose. We also addressed the emerging crisis of OUD in adolescents, where overdose deaths have surged due to illicit fentanyl. We discussed age-appropriate screening, the importance of confidentiality, and the approved use of buprenorphine for those 16 and older. Finally, we examined the unique considerations for treating older adults, including necessary dose adjustments for MOUD due to age-related physiological changes. We clarified the FDA’s risk-benefit guidance on co-prescribing MOUD with other CNS depressants like benzodiazepines, which prioritizes treating the OUD to prevent overdose death.

Conclusion

The treatment of opioid use disorder is inherently complex, and this complexity is magnified when our patients belong to special populations with unique vulnerabilities and needs. A one-size-fits-all approach is not only ineffective but can be actively harmful. The path to better outcomes lies in a commitment to personalized, compassionate, and evidence-based care. This requires us to look beyond the substance use itself and see the whole person—their co-occurring mental health struggles, their life circumstances, their past traumas, and their future hopes. It demands that we stay current with the latest research, understand the pharmacology of the medications we prescribe, and embrace harm reduction as a core tenet of our practice. By treating co-occurring disorders concurrently, championing MOUD in pregnancy, engaging adolescents with sensitivity, and carefully managing care for older adults, we can dismantle barriers to treatment, reduce stigma, and, most importantly, save lives. This work is challenging, but it is among the most vital and rewarding responsibilities we have as healthcare professionals.

Key Insights

• Integrated Treatment is Non-Negotiable: OUD and mental health disorders are deeply intertwined. Treating one without the other is a recipe for failure. Retention in OUD treatment and overall outcomes improve dramatically when co-occurring depression, anxiety, and PTSD are actively treated with therapy and medication.
• MOUD is the Lifesaving Standard in Pregnancy: The evidence is clear and overwhelming. Buprenorphine and methadone are the recommended first-line treatments for OUD in pregnancy. They stabilize the mother’s physiology, improve neonatal outcomes, and are far safer than the cycle of illicit use and withdrawal. Medically supervised withdrawal is contraindicated.
• The Landscape for Youth is Lethal: The adolescent OUD crisis is now defined by fentanyl. Even if experimentation rates are down, mortality is up. This necessitates urgent action focused on naloxone access, education about counterfeit pills, and timely initiation of buprenorphine for teens 16 and older with moderate to severe OUD.
• Risk-Benefit Analysis Must Guide CNS Depressant Co-Prescribing: The fear of combining MOUD with benzodiazepines should not lead to the denial of OUD treatment. The risk of overdose from illicit fentanyl is far greater. The correct approach is to treat the OUD effectively, educate the patient on the combined risks, prescribe naloxone, and work toward a gradual taper of the benzodiazepine where clinically appropriate.
• Trauma-Informed Care is the Foundation: Across all special populations, a history of trauma is a common thread. Adopting a trauma-informed approach that prioritizes safety, trust, collaboration, and empowerment is essential for building the therapeutic alliance necessary for healing and recovery.

References

• Substance Abuse and Mental Health Services Administration. (2023). Key substance use and mental health indicators in the United States: Results from the 2022 National Survey on Drug Use and Health (HHS Publication No. PEP23-07-01-006, NSDUH Series H-58). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration.
• American College of Obstetricians and Gynecologists. (2017). ACOG Committee Opinion No. 711: Opioid use and opioid use disorder in pregnancy. Obstetrics & Gynecology, 130(2), e81-e94.
• Kampman, K., & Jarvis, M. (2015). American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. Journal of Addiction Medicine, 9(5), 358-367.
• S. Food and Drug Administration. (2017). FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or other CNS depressants. [FDA Drug Safety Communication].
• Volkow, N. D., & Blanco, C. (2020). The changing opioid crisis: development, challenges and opportunities. Molecular Psychiatry, 25(1), 218-233.
• Jones, C. M., Compton, W. M., & Volkow, N. D. (2018). The converging crises of opioid addiction, fentanyl, and suicide. JAMA Psychiatry, 75(4), 329-330.
• Friedman, J., & Shover, C. L. (2023). The epidemiology of adolescent-involved overdose deaths in the US, 2019-2021. JAMA Pediatrics, 177(4), 411-414.

Keywords

Opioid Use Disorder, OUD, Co-Occurring Disorders, Mental Health, Depression, Anxiety, PTSD, Trauma-Informed Care, Buprenorphine, Methadone, Naltrexone, MOUD, Serotonin Syndrome, QTc Prolongation, OUD in Pregnancy, Neonatal Opioid Withdrawal Syndrome, NOWS, OUD in Adolescents, Illicit Fentanyl, Older Adults, CNS Depressants, Benzodiazepines, Harm Reduction, Naloxone, Dr. Alexander Jimenez, Health Voice 360.

Disclaimer: This educational post is for informational purposes only and does not constitute medical advice. The information provided is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this webpage.

Personalized Medical Advice Disclaimer: The content presented here is intended for general educational purposes. Every individual’s health situation is unique. All individuals must obtain recommendations for their personal health circumstances directly from their own qualified medical providers. Do not make any changes to your treatment plan without first consulting your healthcare professional.